Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs

Journal of Clinical Gastroenterology

Volumn 49, Issue 4, 2015, Pages 323-328

  Jiang, Jian Ning ^a   Huang, Zhan Lian ^b   He, Li Xia ^a   Huang, Yue Hua ^b   Su, Ming Hua ^a   Xie, Rong ^a   Liang, Yan Xiu ^a   Fu, Wu Dao ^a   Huang, Xiao Hong ^a   Guo, Wen Wen ^a   Zhong, Shao Hua ^a   Liu, Zhi Hong ^a   Li, Shi Hua ^a   Zhu, Tuo Fu ^c   Gao, Zhi Liang ^b  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic hepatitis B; Highly sensitive PCR assay; Relapse; Residual amount of HBV DNA

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; VIRUS DNA; ANTIVIRUS AGENT; NUCLEOTIDE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD LEVEL; CHRONIC HEPATITIS B; DRUG WITHDRAWAL; FEMALE; FLUOROIMMUNOASSAY; HUMAN; IMMUNOASSAY ANALYZER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION SYSTEM; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RELAPSE; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; TREATMENT DURATION; BLOOD; FOLLOW UP; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; MIDDLE AGED; PILOT STUDY; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; TREATMENT WITHDRAWAL;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; NUCLEOTIDES; PILOT PROJECTS; POLYMERASE CHAIN REACTION; RECURRENCE; WITHHOLDING TREATMENT;

EID: 84928367098     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000170     Document Type: Article

References (20)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539.
2. Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921-931.
3. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
4. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastro-enterology. 2006;130:678-686.
5. Jafri SM, Lok AS. Antiviral therapy for chronic hepatitis B. Clin Liver Dis. 2010;14:425-438.
6. Ruhl CE, Everhart JE. Elevated serum alanine aminotransfer-ase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology. 2009;136:477-485.
7. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442-2455.
8. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007; 357:2576-2588.
9. Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 2006;44:108-116.
10. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48: 750-758.
11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131:1743-1751.
12. Liaw Y-F, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561.
13. Yeh CT, Hsu CW, Chen YC, et al. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J Clin Virol. 2009;45:114-118.
14. Fung J, Lai CL, Chan SC, et al. Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. Am J Gastroenterol. 2010;105:1116-1122.
15. Liang Y, Jiang J, Su M, et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther. 2011;34:344-352.
16. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-662.
17. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185.
18. Wang L, Liu F, Liu YD, et al. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepat. 2010;17:298-304.
19. Lee HC, Suh DJ, Ryu SH, et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut. 2003;52:1779-1783.
20. Song BC, Cui XJ, Cho YK, et al. New scoring system for predicting relapse after lamivudine-induced hepatitis B e-antigen loss in chronic hepatitis B patients. Hepatol Res. 2009;39: 1064-1071.